Anemias

Molidustat, an investigational HIF-PHI, is currently in phase 3 of clinical development for the treatment of renal anemia.

100 mg of iron sucrose is the lowest effective monthly dose tested to date in PD patients, according to investigators.

Phase 3 study data show a majority of ESA-treated and ESA-naïve hemodialysis patients taking roxadustat maintained a target hemoglobin range of 10.0 to 12.0 g/dL at 18 to 24 weeks.

Underuse of erythropoiesis-stimulating agents (ESA) and ESA hyporesponsiveness are 2 important reasons for red blood cell transfusion, according to a recent review.

WASHINGTON—Dapagliflozin may correct anemia in patients with type 2 diabetes and chronic kidney disease (CKD), study findings presented at the American Society of Nephrology’s Kidney Week 2019 suggest. Bergur V. Stefansson, MD, PhD, of AstraZeneca in Gothenburg, Sweden, and colleagues analyzed pooled data from 5325 patients who had participated in 14 double-blind randomized trials comparing…

In a 12-week head-to-head study, ferric citrate significantly increased ferritin and hemoglobin levels, whereas ferrous sulfate did not, investigators reported.

WASHINGTON—Functional iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD) is associated with an increased risk for death and cardiovascular-related hospitalization, according to study findings presented at the American Society of Nephrology’s Kidney Week 2019 meeting. Absolute IDA is associated with an elevated risk of hospitalization. A team at Baylor College of Medicine…

Greater annual declines in residual kidney function during the first year on hemodialysis are associated with increasing odds of anemia, study finds.